Drug class
Fibrinolytic Agents clinical trials
A class of medicines: the studies that test any of its 28 members, each study once. Members are as MeSH files each medicine’s actions, and as the NCI Thesaurus classes newer ones.
Keep track of what changes. Save the fibrinolytic agents studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesMedicines in this class
Studies that test each. A study of two counts under both, and once above.
- Ticlopidine
- 2
- Desirudin
- 2
- Letaxaban
- 2
- Parnaparin
- 2
- Monteplase
- 1
- Higenamine
- 1
- Batroxobin
- 1
- Danaparoid
- 1
- Lipoprotein-associated coagulation inhibitor
- 1
- Lemuplamor
- 1
Studies by the year they started
353 studies that test it; most in 2021 (28); 1 more planned to start later
| Year | Studies |
|---|---|
| 1993 | 1 |
| 1998 | 2 |
| 2000 | 2 |
| 2001 | 3 |
| 2002 | 7 |
| 2003 | 9 |
| 2004 | 11 |
| 2005 | 12 |
| 2006 | 17 |
| 2007 | 9 |
| 2008 | 10 |
| 2009 | 10 |
| 2010 | 8 |
| 2011 | 10 |
| 2012 | 9 |
| 2013 | 10 |
| 2014 | 11 |
| 2015 | 10 |
| 2016 | 17 |
| 2017 | 17 |
| 2018 | 17 |
| 2019 | 17 |
| 2020 | 21 |
| 2021 | 28 |
| 2022 | 18 |
| 2023 | 19 |
| 2024 | 15 |
| 2025 | 16 |
| 2026 | 17 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
- Stroke
- 25
Who runs them
Industry 124 · Other 242
Bristol-Myers Squibb (14) · Beijing Tiantan Hospital (12) · Janssen Research & Development, LLC (10) · Boehringer Ingelheim (10) · General Hospital of Shenyang Military Region (7) · Second Affiliated Hospital, School of Medicine, Zhejiang University (7) · Genentech, Inc. (7) · GlycoMimetics Incorporated (7)
Studies
Open first, then newest update. How each study uses a medicine is read from its arms, and is right about nine times in ten.
Testing one of them · 366
- A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen WellRecruitingPhase 3Boehringer IngelheimNCT07361302Written as Tenecteplase
- Tenecteplase or Reteplase as Bridging Thrombolysis Before Thrombectomy in Acute Ischemic Cerebrovascular EventsRecruitingPhase 3Yongjun WangNCT07748039Written as rhTNK-tPA (0.25mg/kg)
- ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632RecruitingPhase 3University of CalgaryNCT06320431Written as Tenecteplase
- Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket TrialRecruitingPhase 2Assistance Publique - Hôpitaux de ParisNCT06381661Written as Plasminogen
- Unknown Time of Onset Stroke RePerfusIon Without Advanced ImagingRecruitingPhase 3First Affiliated Hospital of Guangxi Medical UniversityNCT07475949Written as Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)
- INtra-arterial AltEplase folloWing successfuL reperfusIoN After mEchanical ThrombectomyRecruitingPhase 3115 People's HospitalNCT07727395Written as Alteplase
- Thrombolysis in Factor Xa-inhibitors TrialRecruitingPhase 3Guri HagbergNCT06878066Written as thrombolysis therapy
- Intra-arterial Thrombolysis For Acute Ischemic Stroke With Medium Vessel OcclusionRecruitingPhase 3The First Affiliated Hospital with Nanjing Medical UniversityNCT07668323Written as Recombinant Tissue Plasminogen Activator (rt-PA)
- Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).RecruitingPhase 3King's College Hospital NHS TrustNCT04663750Written as subretinal injection of recombinant TPA (Alteplase) up to a maximum of 25 micrograms in 0.2 mls
- Tenecteplase for Acute Ischemic Stroke Within 4.5 to 6 Hours of Onset (EXIT-BT2)RecruitingPhase 4General Hospital of Shenyang Military RegionNCT06010628Written as Tenecteplase
- Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 HoursRecruitingPhase 3Xuanwu Hospital, BeijingNCT07253181Written as Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)
- Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural EffusionRecruitingEarly Phase 1M.D. Anderson Cancer CenterNCT06184321Written as Alteplase
- CleaRRAflow: Isotonic Solution vs. TPA for IVH ClearanceEnrolling by invitationPhase 4David DornbosNCT07643493Written as Tissue Plasminogen Activator (tPA)
- Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell DiseaseRecruitingPhase 2New York Medical CollegeNCT02675959Written as Defibrotide
- Defibrotide for the Treatment of Severe COVID-19RecruitingPhase 2Brigham and Women's HospitalNCT04652115Written as Defibrotide
- The RAPID - PE Study: RESCUE Advanced Protocol for the Treatment of Pulmonary EmbolismRecruitingNot applicableThrombolex, Inc.NCT06433011Written as r-tPA
- ACT-GLOBAL Adaptive Platform Trial for StrokeRecruitingPhase 3The George InstituteNCT06352632Written as Low-dose intravenous tenecteplase
- rhTNK-tPA for Acute Ischemic Stroke Under Simplified Imaging in the Extended Time WindowRecruitingPhase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07606807Written as Tenecteplase (rhTNK-tPA) (0.25 mg/kg, to maximum of 25mg)
- Efficacy and Safety of Tenecteplase Among acutE Ischemic Stroke Patients With Recent Ingestion of Direct Oral AnticoagulantNot yet recruitingPhase 3Hackensack Meridian HealthNCT07621796Written as Intravenous tenecteplase (TNK)
- Extending the Time Window for Tenecteplase by Recanalization of Basilar Artery Occlusion in Posterior Circulation StrokeRecruitingPhase 2/3University of MelbourneNCT05105633Written as Tenecteplase
See all 366 studies that test one of the fibrinolytic agents →
Codes
What other systems call Fibrinolytic Agents · ClinicalTrials.gg INT007490
- MeSH (NLM) D005343Fibrinolytic AgentsOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D005343 | Fibrinolytic Agents | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.